Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 211Triple Negative Breast Neoplasms 32Stomach Neoplasms 32Inflammatory Breast Neoplasms 21Esophageal Neoplasms 16Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Lymphoma 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2

Interventions

Cytarabine 6Vincristine 4Methotrexate 4Mercaptopurine 4pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Thioguanine 3Dexamethasone 3Daunorubicin 3Cyclophosphamide 3Calcium Dobesilate 3Asparaginase 3prednylidene 2blinatumomab 2asparaginase erwinia chrysanthemi recombinant 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Leucovorin 2Hydrocortisone 2Etoposide 2Doxorubicin 2hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1Spinal Puncture 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Down Syndrome × Epirubicin × Clear all
NCT03286634 2026-05-11

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

National Hospital Organization Nagoya Medical Center

Phase 2 Active not recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡